Background: Treatment of overactive bladder (OAB) with antimuscarinic agents has been shown to improve depression and/or anxiety symptoms. Objectives: The aim of this study was to evaluate the efficacy of mirabegron on OAB symptoms and its effects on depression and/or anxiety of treatment-naïve women with OAB. Methods: Women treated with mirabegron were prospectively evaluated by the OAB symptom score and hospital anxiety and depression Scale before and at 4 and 8 weeks after treatment. Wilcoxon signed-rank and Spearman rank correlation coefficient were used for statistical analyses, and a p value of < 0.05 was considered as significant. Results: Of the 112 patients who were enrolled, 25.0% had been previously diagnosed as having clinical anxiety and 22.3% as having clinical depression. The OAB, anxiety, and depression symptom scores were significantly improved at both 4 and 8 weeks (p < 0.05). Anxiety, but not depression, symptoms were significantly correlated with OAB symptoms. Conclusion: Improvement of OAB symptoms helps relieve anxiety, but not depression.

Keywords:
Mirabegron, Overactive bladder, Anxiety, Depression, Female
1.
Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al.; International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction.
Neurourol Urodyn
. 2010; 29(1): 4–20.
2.
Homma Y, Yamaguchi O, Hayashi K; Neurogenic Bladder Society Committee. An epidemiological survey of overactive bladder symptoms in Japan.
BJU Int
. 2005 Dec; 96(9): 1314–8.
3.
Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States.
World J Urol
. 2003 May; 20(6): 327–36.
4.
Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.
Eur Urol
. 2006 Dec; 50(6): 1306–14.
5.
Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.
BJU Int
. 2008 Jun; 101(11): 1388–95.
6.
Bartoli S, Aguzzi G, Tarricone R. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review.
Urology
. 2010 Mar; 75(3): 491–500.
7.
Lee KS, Yoo TK, Liao L, Wang J, Chuang YC, Liu SP, et al. Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study.
BMC Urol
. 2017 Nov; 17(1): 108.
8.
Marinkovic SP, Rovner ES, Moldwin RM, Stanton SL, Gillen LM, Marinkovic CM. The management of overactive bladder syndrome.
BMJ
. 2012 Apr; 344 apr17 1:e2365.
9.
Yamaguchi O, Nishizawa O, Takeda M, Yokoyama O, Homma Y, Kakizaki H, et al.; Neurogenic Bladder Society. Clinical guidelines for overactive bladder.
Int J Urol
. 2009 Feb; 16(2): 126–42.
10.
Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.
J Pharmacol Exp Ther
. 2007 May; 321(2): 642–7.
11.
Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
Neurourol Urodyn
. 2014 Jan; 33(1): 17–30.
12.
Baxter AJ, Scott KM, Vos T, Whiteford HA. Global prevalence of anxiety disorders: a systematic review and meta-regression.
Psychol Med
. 2013 May; 43(5): 897–910.
13.
Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature.
Psychol Med
. 2013 Mar; 43(3): 471–81.
14.
Chisholm D, Sweeny K, Sheehan P, Rasmussen B, Smit F, Cuijpers P, et al. Scaling-up treatment of depression and anxiety: a global return on investment analysis.
Lancet Psychiatry
. 2016 May; 3(5): 415–24.
15.
Coyne KS, Kvasz M, Ireland AM, Milsom I, Kopp ZS, Chapple CR. Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States.
Eur Urol
. 2012 Jan; 61(1): 88–95.
16.
Rogers R, Bachmann G, Jumadilova Z, Sun F, Morrow JD, Guan Z, et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women.
Int Urogynecol J Pelvic Floor Dysfunct
. 2008 Nov; 19(11): 1551–7.
17.
Staskin DR, Rosenberg MT, Dahl NV, Polishuk PV, Zinner NR. Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.
Int J Clin Pract
. 2008 Jan; 62(1): 27–38.
18.
Esin E, Ergen A, Cankurtaran M, Yavuz BB, Halil M, Ulger Z, et al. Influence of antimuscarinic therapy on cognitive functions and quality of life in geriatric patients treated for overactive bladder.
Aging Ment Health
. 2015; 19(3): 217–23.
19.
Kim KS, Moon HS. Antimuscarinic agent treatment affecting patient-reported outcomes in overactive bladder syndrome with depressive symptoms.
Int Neurourol J
. 2016 Dec; 20(4): 349–55.
20.
Kafri R, Kodesh A, Shames J, Golomb J, Melzer I. Depressive symptoms and treatment of women with urgency urinary incontinence.
Int Urogynecol J Pelvic Floor Dysfunct
. 2013 Nov; 24(11): 1953–9.
21.
Das AK, Carlson AM, Hull M; U.S. MDT-103 Study Group. Improvement in depression and health-related quality of life after sacral nerve stimulation therapy for treatment of voiding dysfunction.
Urology
. 2004 Jul; 64(1): 62–8.
22.
Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, et al.
Development and validity of the overactive bladder symptom score (OABSS)
. Jpn J Urol; 2005. p. 96.
23.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale.
Acta Psychiatr Scand
. 1983 Jun; 67(6): 361–70.
24.
Ishikawa H, Kawakami N, Kessler RC; World Mental Health Japan Survey Collaborators. Lifetime and 12-month prevalence, severity and unmet need for treatment of common mental disorders in Japan: results from the final dataset of World Mental Health Japan Survey.
Epidemiol Psychiatr Sci
. 2016 Jun; 25(3): 217–29.
25.
Burgio KL, Locher JL, Roth DL, Goode PS. Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women.
J Gerontol B Psychol Sci Soc Sci
. 2001 Jan; 56(1): 46–51.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.